Among them, only 255 patients received the first documented dose of a PD-1 or PD-L1 inhibitor after the diagnosis of cancer; no patients were excluded due to a previous history of severe irHAEs before the index start date [Figure 1b]. The gene discussed is PDCD1; the disease is cancer.